want to know more?
+31 (0)20 303 1970

drug discovery in the ubiquitin field

Access to well defined ubiquitinated peptides and conjugates, which could so far not be routinely produced (bio)chemically, is of paramount importance for screening assays for the identification of new drugs, as well as for fundamental research and structural studies. Find out about how our reagents enables research in the three stages of early drug discovery. 


Identify and validate your target using UbiQ Probes.

product info


Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.  

product info

lead on target

Our reagents enable you in lead on target validation and lead optimization.

product info


about our products

UbiQ develops and commercializes ubiquitinated peptides, ubiquitin-based reagents and high throughput assays, which enable and expedite drug discovery in the rapidly expanding ubiquitin field. UbiQ, founded in 2010, is a spin-out of the Netherlands Cancer Institute (NKI), Amsterdam. 

view reagents    more info

custom made reagents

With our UbiQ technologies we are able to fully synthesize site-selective ubiquitinated peptides of native conformation, using automated solid phase peptide synthesis. This enables us to synthesize any custom made peptides.


  • UbiQ-news: Recent Scientific Accomplishments

    08 September 2020

    First of all, we wish all of our customers and partners well during this COVID-19 pandemic.
    Below we have listed some recent publications in which UbiQ participated and that might be of interest to you....(more)



  • In memoriam: Professor Huib Ovaa

    22 May 2020

    On the 19th of May 2020, our co-founder and dear friend Professor Dr. Huib Ovaa passed away from prostate cancer at the age of 46 years. In the past year, Huib has undergone a variety of treatments while continuing to do what he loved so much, being a scientist and mentor. We will miss him and always be grateful for his valuable contributions to our company and the ubiquitin field.
    Farid El Oualid and Alfred Nijkerk

  • UbiQ-news: Scientific accomplishments in 2019 and best wishes for 2020

    17 December 2019

    As we are near the end of this year, we would like to thank our worldwide scientific colleagues for their trust and collaborations. We are proud to be part of various exciting projects, and as such we have outlined below some important published insights which resulted from these collaborations...(more)

  • UbiQ-news: Antibody development by using monoubiquitinated peptides as antigens

    24 April 2019

    Conserved from yeast to human, the histone methyltransferase Dot1 methylates lysine 79 of histone H3 (H3K79) on the nucleosome core. This methylation affects gene expression and DNA damage response, and is enhanced by monoubiquitination of the C-terminus of histone H2B [1 - 4]. Given the promising clinical development of Dot1 inhibitors (e.g. for the treatment of acute leukemia in children [5]), it is important to elucidate the regulatory mechanisms of Dot1 [1 - 4].......(more)